1
by Ho, Chuong, Spry, Carolyn
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects: ...Central Venous Catheters / statistics & numerical data...

2
by Ho, Chuong, Spry, Carolyn
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects: ...Central Venous Catheters / statistics & numerical data...

3
by Deonandan, Raywat, Jones, Sarah
Published 2017
Canadian Agency for Drugs and Technologies in Health
... for the Treatment of Retinal Conditions" established that the efficacy of bevacizumab is not different than...

4
by Deonandan, Raywat, Jones, Sarah
Published 2017
Canadian Agency for Drugs and Technologies in Health
... for the Treatment of Retinal Conditions" established that the efficacy of bevacizumab is not different than...

6
by Banerjee, Srabani, Adcock, Lorna
Published 2017
Canadian Agency for Drugs and Technologies in Health
...) with 27 patients and reported no statistically significant difference between the two modalities...

7
by Banerjee, Srabani, Adcock, Lorna
Published 2017
Canadian Agency for Drugs and Technologies in Health
...) with 27 patients and reported no statistically significant difference between the two modalities...

8
Published 2014
Canadian Agency for Drugs and Technologies in Health
...Diagnosis of psychoses is based on criteria from either the Diagnostic and Statistical Manual (DSM...

9
Published 2014
Canadian Agency for Drugs and Technologies in Health
...Diagnosis of psychoses is based on criteria from either the Diagnostic and Statistical Manual (DSM...

10
by Kaulback, Kellee, Jones, Sarah, Wells, Charlotte, Felipe, Eldiflor
Published 2017
Canadian Agency for Drugs and Technologies in Health
... controlled trials (RCTs) were meta-analyzed, no clinically important differences of HA treatment over IA...

11
by Kaulback, Kellee, Jones, Sarah, Wells, Charlotte, Felipe, Eldiflor
Published 2017
Canadian Agency for Drugs and Technologies in Health
... controlled trials (RCTs) were meta-analyzed, no clinically important differences of HA treatment over IA...

12
Published 2018
Canadian Agency for Drugs and Technologies in Health
... because statistically significant differences were observed in key clinical outcomes when extended DAPT...

13
Published 2018
Canadian Agency for Drugs and Technologies in Health
... because statistically significant differences were observed in key clinical outcomes when extended DAPT...

14
Published 2014
Canadian Agency for Drugs and Technologies in Health
..., and mortality, with an additional cost of US$30,000 per survivor in the US. Different antiseptic solutions...

15
Published 2017
Canadian Agency for Drugs and Technologies in Health
... no apparent differences in efficacy across drug classes, and that sulfonylureas were the most cost-effective...

16
Published 2017
Canadian Agency for Drugs and Technologies in Health
... no apparent differences in efficacy across drug classes, and that sulfonylureas were the most cost-effective...

17
Published 2013
Canadian Agency for Drugs and Technologies in Health

18
Published 2012
Canadian Agency for Drugs and Technologies in Health

19
Published 2013
Canadian Agency for Drugs and Technologies in Health

20
Published 2012
Canadian Agency for Drugs and Technologies in Health